8 recruiting, 6 completed, 2 active not recruiting, 2 withdrawn. 8 Phase 1, 7 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Recruiting 3, Withdrawn 2 |
| Phase 2 | 7 | Recruiting 3, Completed 2, Terminated 1, Withdrawn 1 |
| Not applicable | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow CNS Tumor: new trials by email Literature Review of CNS Tumor trials Research Report on CNS Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). BCB-276 - Diffuse Intrinsic Pontine Glioma, DIPG | Phase 2 | Recruiting | BrainChild Bio, Inc | 75 | 2026-09-04 | 2026-10-28 |
| Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors Bulk RNA Sequencing, Immunohistochemistry (IHC) - CNS Tumor, Solid Tumor | Not applicable | Not yet recruiting | Dana-Farber Cancer Institute | 130 | 2026-09-01 | 2026-08-31 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-05-13 |
| Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors Neurological assessment - CNS Tumor, Artificial Intelligence (AI) | Recruiting | Tata Memorial Centre | 600 | 2026-02-20 | 2026-02-24 | |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors Idasanutlin, Selinexor - Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | St. Jude Children's Research Hospital | 2024-03-01 | 2024-03-27 | |
| Artificial Intelligence in CNS Radiation Oncology The images (CT, MRI, PET) used for RT planning, mid-treatment imaging as part of IGRT or disease evaluation, and response assessment/ surveillance post-RT - CNS Tumor | Recruiting | Tata Memorial Centre | 6000 | 2023-09-13 | 2025-04-09 | |
| Characterizing Sleep Among Long-term Survivors of Childhood Cancer Neurocognitive (Thinking) Testing, CNS Vital Signs (Thinking) Testing, Health Questionnaires, Sleep Surveys & Sleep Diary - ALL, Adult, CNS Tumor | Active not recruiting | St. Jude Children's Research Hospital | 199 | 2023-04-17 | 2026-08-19 | |
| Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors Radiation Therapy - CNS Germinoma, CNS Tumor | Recruiting | National Cancer Center, Korea | 400 | 2022-08-05 | 2023-08-08 | |
| Artificial Intelligence Neuropathologist CNS Tumor, Neuropathology | Unknown | Huashan Hospital | 1000 | 2022-05-01 | 2022-03-29 | |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling avapritinib - Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1 / Phase 2 | Completed | Blueprint Medicines Corporation | 29 | 2022-02-24 | 2026-01-13 |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Infigratinib - Advanced Solid Tumor, CNS Tumor | Phase 1 / Phase 2 | Withdrawn | Helsinn Healthcare SA | 2021-10-01 | 2023-02-23 | |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) - Diffuse Midline Glioma (DMG), Glioblastoma | Phase 1 | Recruiting | Sabine Mueller, MD, PhD | 208 | 2021-08-23 | 2026-06-11 |
| Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer Integrative neuromuscular training (INT), Active control group: home-based training program, motivational counseling session - Pediatric Cancer, Leukemia | Not applicable | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 132 | 2021-01-26 | 2025-06-11 |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Nivolumab and Entinostat - CNS Tumor, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University Hospital Heidelberg | 91 | 2020-05-26 | 2024-02-07 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Prexasertib, Cyclophosphamide, Gemcitabine - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | St. Jude Children's Research Hospital | 21 | 2019-08-08 | 2025-02-07 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Effectiveness of Care in Certified Cancer Centres in Germany Oncological certification - Colorectal Cancer, Breast Cancer | Completed | Technische Universität Dresden | 670000 | 2017-05-01 | 2022-08-23 | |
| Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry CNS Tumor | Completed | Arbor Pharmaceuticals, Inc. | 272 | 2016-04-26 | 2025-11-10 |
Showing 20 of 21. Sign in to see all of them.
Central Nervous System Neoplasms (21) · Brain Neoplasms (6) · Glioma (6) · Neoplasms (5) · Recurrence (3) · Breast Neoplasms (2) · Endometrial Neoplasms (2) · Ependymoma (2) · Glioblastoma (2) · Medulloblastoma (2) · Meningioma (2) · Microphthalmia, Isolated, with Coloboma 5 (2) · Neurilemmoma (2) · Neurofibroma (2) · Ovarian Neoplasms (2)
Neoplasms by Site (21) · Nervous System Diseases (21) · Nervous System Neoplasms (21) · Neoplasms (16) · Neoplasms by Histologic Type (15) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Glandular and Epithelial (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neoplasms, Neuroepithelial (8) · Brain Diseases (6) · Central Nervous System Diseases (6) · Immune System Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
Filgrastim (3) · Gemcitabine (3) · Granulocyte Colony-Stimulating Factor (3) · Cyclophosphamide (2) · Radiotherapy (2) · pegfilgrastim (2) · Carboplatin (1) · Doxorubicin (1) · Etoposide (1) · Fluorouracil (1) · Folfox protocol (1) · IFL protocol (1) · Immunohistochemistry (1) · Leucovorin (1) · Magnetic Resonance Imaging (1)
St. Jude Children's Research Hospital (5) · Tata Memorial Centre (2) · Arbor Pharmaceuticals, Inc. (1) · Blueprint Medicines Corporation (1) · BrainChild Bio, Inc (1) · Burzynski Research Institute (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1) · Helsinn Healthcare SA (1) · Huashan Hospital (1) · National Cancer Center, Korea (1) · Pheast Therapeutics (1) · Reveal Pharmaceuticals Inc. (1) · Sabine Mueller, MD, PhD (1) · Technische Universität Dresden (1)
United States (13) · Germany (4) · Australia (2) · Austria (2) · Canada (2) · France (2) · India (2) · Netherlands (2) · South Korea (2) · Switzerland (2) · Brazil (1) · China (1) · Denmark (1) · Italy (1) · Jordan (1)
Giles W. Robinson, MD (2) · Amar Gajjar, MD (1) · Cori Abikoff, MD (1) · Daniel Moreira, MD, MEd (1) · Hanne B. Larsen, As. Prof (1) · Jinsong Wu, Ph.D. & M.D (1) · Joo-young Kim, M.D., Ph.D. (1) · Kevin Krull, PhD (1) · Olaf Witt (1) · Sabine Mueller, MD, PhD (1) · Stanislaw R. Burzynski, MD, PhD (1) · Steven Dubois, MD,MS (1)
PMID 29206049, PMID 32503469, PMID 35157764, PMID 35359909, PMID 35672675, PMID 41188998, PMID 41213248, PMID 41256696
2018 (1), R01CA266596 (1), R44CA261240 (1)